公司资料
Neurogene 股价、新闻与催化剂
- 股票代码:
- NGNE
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
26.55 USD (-4.57%)
收盘价
最后更新: 2026年10月1日
413M USD
市值
股价为何变动
截至 2026年10月1日，NGNE 下跌 4.57%，收于 $26.55。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Neurogene is a gene-therapy company focused on rare neurological diseases. Its story is centered on bringing genetic medicine to severe CNS disorders with very high unmet need.
所在地与行业分类
Neurogene is headquartered in the United States and listed on NASDAQ. It sits in gene therapy and neuroscience biotechnology.
商业模式特征
The company depends on clinical progress, manufacturing execution, and the ability to fund a narrow rare-disease pipeline. Investors watch early data and safety closely.
生物医药行业定位
Neurogene occupies a premium but high-risk gene-therapy niche within biotech. The stock is catalyst-sensitive because the company’s value is tightly linked to a small set of gene-therapy assets.
未来催化剂
- Neurogene’s catalysts are NGN-401 and the Rett-syndrome / neurogenetic platform, with each update potentially moving the stock quickly. The company remains early and highly data-dependent.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。